These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 33418062)

  • 1. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy
    Denkert C; Untch M; Benz S; Schneeweiss A; Weber KE; Schmatloch S; Jackisch C; Sinn HP; Golovato J; Karn T; Marmé F; Link T; Budczies J; Nekljudova V; Schmitt WD; Stickeler E; Müller V; Jank P; Parulkar R; Heinmöller E; Sanborn JZ; Schem C; Sinn BV; Soon-Shiong P; van Mackelenbergh M; Fasching PA; Rabizadeh S; Loibl S
    Ann Oncol; 2021 Apr; 32(4):500-511. PubMed ID: 33418062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.
    Farmanbar A; Firouzi S; Kneller R; Khiabanian H
    J Transl Med; 2022 Feb; 20(1):65. PubMed ID: 35109853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
    Diossy M; Reiniger L; Sztupinszki Z; Krzystanek M; Timms KM; Neff C; Solimeno C; Pruss D; Eklund AC; Tóth E; Kiss O; Rusz O; Cserni G; Zombori T; Székely B; Kulka J; Tímár J; Csabai I; Szallasi Z
    Ann Oncol; 2018 Sep; 29(9):1948-1954. PubMed ID: 29917049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.
    Loibl S; Treue D; Budczies J; Weber K; Stenzinger A; Schmitt WD; Weichert W; Jank P; Furlanetto J; Klauschen F; Karn T; Pfarr N; von Minckwitz G; Möbs M; Jackisch C; Sers C; Schneeweiss A; Fasching PA; Schem C; Hummel M; van Mackelenbergh M; Nekljudova V; Untch M; Denkert C
    Clin Cancer Res; 2019 Jul; 25(13):3986-3995. PubMed ID: 30979740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients.
    Zhou Z; Ding Z; Yuan J; Shen S; Jian H; Tan Q; Yang Y; Chen Z; Luo Q; Cheng X; Yu Y; Niu X; Qian L; Chen X; Gu L; Liu R; Ma S; Huang J; Chen T; Li Z; Ji W; Song L; Shen L; Jiang L; Yu Z; Zhang C; Tai Z; Wang C; Chen R; Carbone DP; Xia X; Lu S
    J Hematol Oncol; 2022 May; 15(1):62. PubMed ID: 35585646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome.
    Powles RL; Wali VB; Li X; Barlow WE; Nahleh Z; Thompson AM; Godwin AK; Hatzis C; Pusztai L
    Clin Cancer Res; 2020 Apr; 26(8):1977-1984. PubMed ID: 31919134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
    Tan SH; Sapari NS; Miao H; Hartman M; Loh M; Chng WJ; Iau P; Buhari SA; Soong R; Lee SC
    PLoS One; 2015; 10(12):e0142466. PubMed ID: 26630576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
    Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
    Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
    Fasching PA; Link T; Hauke J; Seither F; Jackisch C; Klare P; Schmatloch S; Hanusch C; Huober J; Stefek A; Seiler S; Schmitt WD; Uleer C; Doering G; Rhiem K; Schneeweiss A; Engels K; Denkert C; Schmutzler RK; Hahnen E; Untch M; Burchardi N; Blohmer JU; Loibl S;
    Ann Oncol; 2021 Jan; 32(1):49-57. PubMed ID: 33098995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
    Barroso-Sousa R; Jain E; Cohen O; Kim D; Buendia-Buendia J; Winer E; Lin N; Tolaney SM; Wagle N
    Ann Oncol; 2020 Mar; 31(3):387-394. PubMed ID: 32067680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery.
    Zhu Y; Iwamoto T; Kajiwara Y; Takahashi Y; Kochi M; Shien T; Taira N; Toyooka S; Doihara H
    Breast Cancer; 2023 Jan; 30(1):56-67. PubMed ID: 35994199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.